REGN
Bayer Ag - Approximately 90% of Aflibercept 8 Mg Patients Were Extended to Every 8-Week Dosing and Maintained Their Interval Through 36 Weeks
时间：2024-12-17 20:01:07 市场： 美股 综合
Regeneron Pharmaceuticals Inc - Supplementary Biologics License Application Planned for Q1 2025
时间：2024-12-17 20:00:00 市场： 美股 综合
Regeneron to Highlight Pioneering Pipeline Progress Across Multiple Modalities Spanning 10 Types of Blood Cancers and Disorders at Ash
时间：2024-11-13 20:00:36 市场： 综合 美股
Regeneron Pharmaceuticals Inc : Guggenheim Cuts Target Price to $1200 From $1300
时间：2024-11-04 19:24:41 市场： 美股 综合
Regeneron Pharmaceuticals Inc : Leerink Partners Cuts Target Price to $880 From $1077
时间：2024-11-01 18:12:54 市场： 美股 综合
Regeneron Pharmaceuticals Inc Files for Mixed Shelf; Size Not Disclosed - SEC Filing
时间：2024-11-01 04:34:47 市场： 美股 综合
Roche Executive Graham: We Don’t See Anything That Is Slowing Down Momentum in Demand for Eye Drug Vabysmo, It Is Competing Exceptionally Well
时间：2024-10-23 15:28:46 市场： 美股 综合
Amgen Says It Is Launching Biosimilar of Eye Drug Eylea After U.S. Appeals Court Ruling in Regeneron Patent Case
时间：2024-10-23 02:51:54 市场： 美股 综合
Three-Year Results for Eylea Hd® (Aflibercept) Injection 8 Mg Demonstrate Continued Durable Vision Gains and Anatomic Improvements With Extended Dosing Intervals in Patients With Diabetic Macular Edema
时间：2024-10-19 05:05:00 市场： 美股 综合
Regeneron Pharmaceuticals Inc : Truist Securities Cuts Target Price to $1137 From $1200
时间：2024-10-16 19:48:27 市场： 美股 综合